E-viri
Recenzirano
-
Jehn, Christian F; Hemmati, Philipp; Lehenbauer-Dehm, Silvia; Kümmel, Sherko; Flath, Bernd; Schmid, Peter
Clinical breast cancer, 12/2016, Letnik: 16, Številka: 6Journal Article
Micro-Abstract Limited information exists regarding the efficacy and toxicity of an anthracycline rechallenge in heavily pretreated patients with metastatic breast cancer. This prospective phase 2 trial with 25 patients demonstrated a clinical benefit in 23% of the patients for a median duration of 12.5 months. The toxicity profile is reasonable for such advanced disease.
